Hubert Czerniak - Witamina dobrego nastroju o wielkiej sile działania / B1, czyli tiamina

The speaker explains that because thiamine cannot accumulate in the body due to rapid renal clearance, a single daily dose leaves large gaps where tissues are unsupported. He advises that dividing the daily amount into morning, midday, and evening doses keeps a consistent supply, which is especially important for the brain's continuous energy demands and neurotransmitter reuptake. He presents this as the optimal way to mimic the body's steady-state needs and maximize clinical effects, contrasting with the common practice of taking all at once.

He notes that B1 is a coenzyme for approximately 20 enzymes, which typically need magnesium, zinc, cobalt, and molybdenum to function. He specifically mentions that magnesium and zinc occupy binding sites on the NMDA receptor, helping to dampen excitotoxicity. By stressing that heavy metals like mercury have a million-fold higher affinity for these enzyme centers, he implies that adequate magnesium and zinc can competitively protect against heavy-metal disruption. Thus, combining B1 with these minerals is not just about general synergy but also about safeguarding enzyme activity in a toxic environment.

The speaker defends the traditional practice of drinking tea with lemon, which some modern sources have questioned. He argues that our ancestors observed nature and knew what they were doing: the vitamin C in lemon juice shields B1 from tannin-induced degradation. For heavy coffee drinkers (5–6 cups a day), he advises similarly high vitamin C intake. He specifically mentions that while 'vitamin C' colloquially makes us think of lemon, oranges and grapefruits have even more, and quince is extremely rich. This practical advice aims to maintain B1 bioavailability in those whose diets or habits would otherwise deplete it.

He contrasts the typical oral maintenance dose (25–100 mg) with the 2–3 g daily injectable dose used in Wernicke's encephalopathy—a life-threatening B1 deficiency state often seen in alcoholism. He then extends this high-dose logic to Alzheimer's, Parkinson's, MS, and ALS, arguing that these conditions share underlying energy failure and glutamate excitotoxicity that large amounts of B1 might correct. He notes that such high doses are usually given parenterally to bypass any absorption issues, and that occasionally skin reactions occur but are manageable. This protocol is framed as a medical intervention, not a casual supplement regimen.

The speaker cites a finding that 6 weeks of B1 supplementation boosts ejection fraction by 22%. He ties this to the fact that thiamine concentrates in the heart, brain, liver, and kidneys—organs with high energy turnover. He further mentions that B1 is useful in all heart diseases, including tachycardia and hypertension, and that its role in acetylcholine production stabilizes rhythm. While he doesn't detail the exact dose used in the study, he implies that consistent supplementation yields measurable functional cardiac improvement, making it an easy adjunct to standard care.

Building on his earlier explanation of excitotoxicity, he argues that when a child who had a normal Apgar score suddenly loses motor or speech milestones, the cause is likely heavy-metal-induced NMDA overactivation and thiamine-dependent glial failure. He insists that neurologists should not prescribe psychotropic drugs but immediately give a large dose of B1, analogous to the life-saving protocol for Wernicke's encephalopathy. He frames this as an emergency intervention: if caught early, no permanent effects will remain; if missed, the result is full-blown neurodegeneration requiring long, expensive treatment. This protocol is his direct challenge to conventional pediatric neurology.

The speaker notes that vitamin B1 accumulates in the heart, implying that deficiency may directly impair cardiac electrical stability. He states that in his practice, patients taking a B complex supplement have seen AF episodes disappear, allowing them to avoid antiarrhythmics. He links this effect to B1's role in producing acetylcholine, a neurotransmitter essential for neuromuscular and cardiac conduction. Although he provides no trial data, he frames this as a practical, side-effect-free approach worth trying in rhythm disorders. He also mentions that B1 is beneficial in all heart diseases, citing a 22% increase in ejection fraction with 6-week supplementation as supporting evidence for its cardiac importance.

He explains that B1 acts on synaptic and mitochondrial membranes and participates in the reuptake of serotonin and GABA in the cerebellum, hippocampus, and thalamus. He emphasizes that even in people with normal plasma thiamine, 50 mg daily improves mood, communication, and memory while reducing aggression and mental fog. He then poses a rhetorical challenge: 'Is it better to give vitamin B1, which is non-toxic and natural, or serotonin reuptake inhibitors, psychiatric drugs that have a litany of side effects? The choice belongs to us doctors and you patients.' This frames B1 not merely as a supportive nutrient but as a primary mood modulator targeting the same mechanism as prescription drugs, but without toxicity. The underlying assumption is that many mood disorders stem from suboptimal brain energy metabolism and neurotransmitter recycling, correctable by adequate B1.

The speaker states: 'Until recently, the critical point was thought to be neuronal damage; latest studies show the critical point is damage and insufficiency of glial cells.' He describes astrocytes that provide structural scaffolding and regulate glutamate, oligodendrocytes that wrap myelin, unique human NG2 cells, and microglia as brain macrophages. He mentions Professor Jerzy Zięba had emphasized microglia's role. He then connects this to thiamine: lack of B1 reduces glutamate transporter activity on astrocytes, leading to extracellular glutamate accumulation and excitotoxic damage via NMDA receptors. B1 supplementation can restore astrocyte function and prevent neurodegeneration. This paradigm implies that early intervention with B1 could preserve glial function and stop diseases like MS and ALS, which he claims are currently considered incurable.

He explains that B1 inhibits the oxidation of unsaturated lipids—the ones that form atherosclerotic plaques—and itself acts as an antioxidant. Crucially, it also stimulates glutathione reductase, the enzyme that recycles oxidized glutathione back to its active form. He then remarks: 'giving vitamin B1 can help us a lot and we don't necessarily have to incur the costs of administering glutathione, which is very expensive and lately hard to obtain.' He positions B1 as a practical, widely available means to boost endogenous antioxidant defense, which could be particularly useful in chronic degenerative and cardiovascular diseases where oxidative stress is high.

He references earlier content about how mercury (thimerosal) and aluminum hydroxide trigger chronic overactivation of NMDA receptors, leading to excitotoxicity. He explains that this overload causes extracellular glutamate buildup and loss of glutamate-uptake astrocytes—a process driven by thiamine deficiency. He then states that when a child who had a 10 Apgar score suddenly stops walking or talking, high-dose B1 should be administered immediately, analogous to Wernicke's encephalopathy treatment. He explicitly warns neurologists: 'not neuroleptics, but a large dose of vitamin B1.' If caught early, this can halt permanent neurodegeneration; if delayed, the damage becomes irreversible and expensive to treat. This positions B1 as a potential emergency intervention for acute neurodevelopmental regression attributed to heavy metals.